2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Rodríguez L, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clinical And Research Reports 2022, 3: 100385. PMID: 36065449, PMCID: PMC9440305, DOI: 10.1016/j.jtocrr.2022.100385.Peer-Reviewed Original ResearchProgression-free survivalPhase 1/2 studyMedian investigator-assessed progression-free survivalInvestigator-assessed progression-free survivalMedian overall survivalPhase 2 trialLong-term efficacyOverall survivalPhase 1/2Arm AStudy endMedian intracranial progression-free survivalIntracranial progression-free survivalRandomized phase 2 trialNew safety signalsIndependent review committeeArm B.Advanced malignanciesBrain metastasesManageable safetyArm BPositive NSCLCSafety signalsNSCLCPatients
2021
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
Gettinger S, Huber R, Kim D, Bazhenova L, Hansen K, Tiseo M, Langer C, Paz-Ares L, West H, Reckamp K, Weiss G, Smit E, Hochmair M, Kim S, Ahn M, Kim E, Groen H, Pye J, Vranceanu F, Camidge D. Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials. Journal Of Clinical Oncology 2021, 39: 9071-9071. DOI: 10.1200/jco.2021.39.15_suppl.9071.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalPhase 1/2 studyIndependent review committeeArm A/BPhase 2 trialOverall survivalPhase 1/2Arm AKaplan-MeierRefractory non-small cell lung cancerMetastatic non-small cell lung cancerHigher median progression-free survivalMedian progression-free survivalTreatment-emergent adverse eventsALK tyrosine kinase inhibitorsKinase inhibitorsBaseline brain metastasesObjective response rateOpen-label trialNew safety signalsCell lung cancerDuration of responseTreatment of patientsLong-term efficacy
2015
3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study
Camidge D, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Dorer D, Rivera V, Conlan M, Kerstein D, Gettinger S. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study. European Journal Of Cancer 2015, 51: s616. DOI: 10.1016/s0959-8049(16)31703-8.Peer-Reviewed Original Research99O Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses
Rosell R, Gettinger S, Bazhenova L, Langer C, Salgia R, Gold K, Shaw A, Dorer D, Kerstein D, Camidge D. 99O Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses. Annals Of Oncology 2015, 26: i29. DOI: 10.1093/annonc/mdv050.03.Peer-Reviewed Original Research